{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hsiao YJ"],"funding":["Ministry of Science and Technology, Taiwan,","National Science and Technology Council (NSTC), Taiwan.","Ministry of Science and Technology, Taiwan","National Science and Technology Council"],"pagination":["137"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11451087"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Objective
As the global use of extracorporeal membrane oxygenation (ECMO) treatment increases, survival rates have not correspondingly improved, emphasizing the need for refined patient selection to optimize resource allocation. Currently, prognostic markers at the molecular level are limited.Methods
Thirty-four cardiogenic shock (CS) patients were prospectively enrolled, and peripheral blood mononuclear cells (PBMCs) were collected at the initiation of ECMO (t0), two-hour post-installation (t2), and upon removal of ECMO (tr). The PBMCs were analyzed by comprehensive epigenomic assays. Using the Wilcoxon signed-rank test and least absolute shrinkage and selection operator (LASSO) regression, 485,577 DNA methylation features were analyzed and selected from the t0 and tr data"],"journal":["Clinical epigenetics"],"pubmed_title":["Epigenomic biomarkers insights in PBMCs for prognostic assessment of ECMO-treated cardiogenic shock patients."],"pmcid":["PMC11451087"],"funding_grant_id":["NSC 102-2325-B-002-009","NSC 100-2314-B-002-018-MY2","MOST 109-2314-B-002-218","MOST 102-2325-B-002-078","MOST 103-2325-B-002-026"],"pubmed_authors":["Kuo SW","Wang CH","Yu SL","Lin CA","Chi NH","Su KY","Yu HY","Chiang SC","Lin CY","Hsu LM","Hsiao YJ","Chen YS","Chen HY","Hong TH","Ko WJ","Cheng CL","Chen YM"],"additional_accession":[]},"is_claimable":false,"name":"Epigenomic biomarkers insights in PBMCs for prognostic assessment of ECMO-treated cardiogenic shock patients.","description":"Objective
As the global use of extracorporeal membrane oxygenation (ECMO) treatment increases, survival rates have not correspondingly improved, emphasizing the need for refined patient selection to optimize resource allocation. Currently, prognostic markers at the molecular level are limited.Methods
Thirty-four cardiogenic shock (CS) patients were prospectively enrolled, and peripheral blood mononuclear cells (PBMCs) were collected at the initiation of ECMO (t0), two-hour post-installation (t2), and upon removal of ECMO (tr). The PBMCs were analyzed by comprehensive epigenomic assays. Using the Wilcoxon signed-rank test and least absolute shrinkage and selection operator (LASSO) regression, 485,577 DNA methylation features were analyzed and selected from the t0 and tr data","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-15T04:18:35.196Z","creation":"2025-04-04T00:34:57.204Z"},"accession":"S-EPMC11451087","cross_references":{"pubmed":["39363385"],"doi":["10.1186/s13148-024-01751-6"]}}